BG
ACRS icon

BlackRock Group’s Aclaris Therapeutics ACRS Stock Holding History

BlackRock Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$78K Buy
+2,892
New +$73.7K ﹤0.01% 2867

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Group's ACRS Position: Q4 2016 in Review

BlackRock Group opened a new position in Aclaris Therapeutics (ACRS) in Q4 2016: 2,892 shares worth $78K. The stake represents ﹤0.01% of the portfolio and ranks #2867 among its holdings.

100 funds tracked by Wall St. Rank hold ACRS as of Q4 2016.

  • BlackRock Group held 2,892 shares of Aclaris Therapeutics worth $78K as of Q4 2016.
  • Aclaris Therapeutics was a new BlackRock Group position in Q4 2016.
  • Aclaris Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2867 holding.
  • 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.